Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer
- PMID: 9869512
- DOI: 10.1007/BF02303476
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer
Abstract
Background: Induction chemotherapy has become the standard of care for patients with locally advanced breast cancer (LABC) and currently is being evaluated in prospective clinical trials in patients with earlier-stage disease. To better gauge the role of axillary lymph node dissection in patients with LABC this study was performed to assess initial axillary status on physical and ultrasound examination, axillary tumor downstaging following induction chemotherapy, and the accuracy of physical examination compared with axillary sonography in predicting which patients will have axillary lymph node metastases found on pathologic examination.
Methods: Between 1992 and 1996, 147 consecutive patients with LABC were registered in a prospective trial of induction chemotherapy using 5-fluorouracil, doxorubicin, and cyclophosphamide. Physical and ultrasound examinations of the axilla were performed at diagnosis and after induction chemotherapy. Segmental resection with axillary lymph node dissection or modified radical mastectomy was performed, followed by postoperative chemotherapy and irradiation of the breast or chest wall and regional lymphatics.
Results: Following induction chemotherapy, 43 (32%) of the 133 patients with clinically positive lymph nodes on initial examination had axillary tumor downstaging as assessed by physical and ultrasound examination. The sensitivity of axillary sonography in identifying axillary metastases was significantly higher than that of physical examination (62% vs. 45%, P=.012). The specificity of physical examination (84%) was higher than that of sonography (70%), but the difference did not reach statistical significance. Among the 55 patients in whom the findings of both physical and ultrasound examination of the axilla were negative following induction chemotherapy, 29 patients (53%) were found to have axillary lymph node metastases on pathologic examination of the axillary contents. However, 28 (97%) of these patients had either 1 to 3 positive lymph nodes or only micrometastases 2 to 5 mm in diameter.
Conclusions: Preoperative clinical assessment of the axilla by physical examination combined with ultrasound examination is not completely accurate in predicting metastases in patients with LABC following tumor downstaging. However, patients with negative findings on both physical and ultrasound examinations of the axilla may be potential candidates for omission of axillary dissection if the axilla will be irradiated because minimal axillary disease remains. Patients who have positive findings on preoperative physical or ultrasound examinations should receive axillary dissection to ensure local control. A prospective randomized trial of axillary dissection versus axillary radiotherapy in patients with a clinically negative axilla following induction chemotherapy is currently underway.
Comment in
-
Role of axillary lymph node dissection after tumor downstaging.Ann Surg Oncol. 1998 Dec;5(8):665-6. doi: 10.1007/BF02303473. Ann Surg Oncol. 1998. PMID: 9869509 No abstract available.
Similar articles
-
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.Am J Surg. 1998 Dec;176(6):502-9. doi: 10.1016/s0002-9610(98)00253-0. Am J Surg. 1998. PMID: 9926779 Clinical Trial.
-
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6. Cancer J Sci Am. 1998. PMID: 9689981 Clinical Trial.
-
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.Clin Cancer Res. 1997 Sep;3(9):1565-9. Clin Cancer Res. 1997. PMID: 9815844
-
Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.J Surg Oncol. 2004 Mar;85(3):102-11. doi: 10.1002/jso.20022. J Surg Oncol. 2004. PMID: 14991881 Review.
-
[Management of the axilla in breast cancer: evidences and unresolved issues].Orv Hetil. 2001 Sep 9;142(36):1941-50. Orv Hetil. 2001. PMID: 11680099 Review. Hungarian.
Cited by
-
Sentinel lymph node biopsy alone after neoadjuvant chemotherapy in patients with initial cytology-proven axillary node metastasis.J Breast Cancer. 2015 Mar;18(1):22-8. doi: 10.4048/jbc.2015.18.1.22. Epub 2015 Mar 27. J Breast Cancer. 2015. PMID: 25834607 Free PMC article.
-
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.Breast Cancer Res. 2016 Mar 8;18(1):28. doi: 10.1186/s13058-016-0684-6. Breast Cancer Res. 2016. PMID: 26951131 Free PMC article. Review.
-
Can We Use MRI and US to Predict Axillary Node Response in Breast Cancer?Radiology. 2019 Oct;293(1):58-59. doi: 10.1148/radiol.2019191642. Epub 2019 Aug 13. Radiology. 2019. PMID: 31414961 Free PMC article. No abstract available.
-
Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S103-11. doi: 10.1007/s00259-004-1532-y. Epub 2004 Apr 22. Eur J Nucl Med Mol Imaging. 2004. PMID: 15103507 Review.
-
Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1. Ann Surg Oncol. 2014. PMID: 24788555 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical